<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02815839</url>
  </required_header>
  <id_info>
    <org_study_id>SHR4640-101</org_study_id>
    <nct_id>NCT02815839</nct_id>
  </id_info>
  <brief_title>Single Dose Study of SHR4640 in Healthy Subjects</brief_title>
  <official_title>A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Safety, Tolerability, Food Effect, Pharmacokinetics, and Pharmacodynamics of Single Doses of SHR4640 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu HengRui Medicine Co., Ltd.</source>
  <brief_summary>
    <textblock>
      The objective of the study is to assess the safety, tolerance, food effect, pharmacokinetic
      and pharmacodynamic properties of single dose adminstration of SHR4640 in healthy volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 2015</start_date>
  <completion_date type="Actual">February 2017</completion_date>
  <primary_completion_date type="Actual">February 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events</measure>
    <time_frame>Clinical significant changes from baseline up to to Day 15; from baseline up to Day 19 for 7.5mg dose group</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Peak Plasma Concentration (Cmax)</measure>
    <time_frame>up to day 4; up to day 11 for 7.5mg dose group</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration versus time curve (AUC)</measure>
    <time_frame>up to day 4; up to day 11 for 7.5mg dose group</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half-time (T1/2)</measure>
    <time_frame>up to day 4; up to day 11 for 7.5mg dose group</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to the peak plasma concentration (Tmax)</measure>
    <time_frame>up to day 4; up to day 11 for 7.5mg dose group</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax of SHR4640 dosed after high-fat meal in 7.5mg dose group</measure>
    <time_frame>up to day 11</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC of SHR4640 dosed after high-fat meal in 7.5mg dose group</measure>
    <time_frame>up to day 11</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T1/2 of SHR4640 dosed after high-fat meal in 7.5mg dose group</measure>
    <time_frame>up to day 11</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax of SHR4640 dosed after high-fat meal in 7.5mg dose group</measure>
    <time_frame>up to day 11</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in serum uric acid concentration from baseline</measure>
    <time_frame>up to day 4; up to day 11 for 7.5mg dose group</time_frame>
    <description>absolute and percent changes in serum acid concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in urinary uric acid excretion from baseline</measure>
    <time_frame>up to day 4; up to day 11 for 7.5mg dose group</time_frame>
    <description>percent changes in urinary uric acid excretion from baseline</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Gout; Hyperuricemia</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2.5-mg SHR4640 or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5-mg SHR4640 or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>7.5-mg SHR4640 or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10-mg SHR4640 or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20-mg SHR4640 or placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SHR4640</intervention_name>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_label>Cohort 5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_label>Cohort 5</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Body weight≥50, BMI:19-24kg/m2;

          -  Screening serum urate level ≤ 4.5 mg/dL for male and ≤ 3.5 mg/dL for female;

          -  Medically stable based on physical examination, medical history, laboratory results,
             vital sign measurements, and 12-lead electrocardiogram (ECG) at screening;

        Exclusion Criteria:

          -  History of hyperuricemia or gout.

          -  Pregnancy or breastfeeding;

          -  History or suspicion of kidney stones;

          -  serum creatinine＞1.5mg/dl for male, ＞1.2mg/dl for female;

          -  alanine aminotransferase and/or aspartate aminotransferase＞2 upper limit of normal, or
             total bilirubin＞2.5 upper limit of normal.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Southwest Hospital</name>
      <address>
        <city>Chongqing</city>
        <state>Sichuan</state>
        <zip>400038</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 27, 2016</study_first_submitted>
  <study_first_submitted_qc>June 23, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 28, 2016</study_first_posted>
  <last_update_submitted>February 26, 2017</last_update_submitted>
  <last_update_submitted_qc>February 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>urate transporter 1</keyword>
  <keyword>SHR4640</keyword>
  <keyword>single ascending dose</keyword>
  <keyword>pharmacokinetics</keyword>
  <keyword>pharmacodynamics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperuricemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

